CochranLab

[CochranLab @CochranLab]

Check out our review article describing recent updates in LAG3 biology and therapeutics in @TrendsinPharma with @jwang133 and @Curie_Bio colleagues: https://t.co/HbTVl9BziF

[CochranLab @CochranLab]

Proud to have our work with @CarolynBertozzi
and Ron Levy on tumor-targeted cancer therapeutics featured in the @StanfordOTL annual report https://t.co/LKFbrmScV0; now being developed at TwoStep Therapeutics, led by lab alum Caitlyn Miller @CaitlynBioE

[CochranLab @CochranLab]

Congrats to lab alum Bob Chen and the @OmniAbTech team on winning "Best in Show" at @PEGSboston for their innovative and impactful xPloration B cell/ Ab screening platform.

[PEGS Summit @PEGSboston]

🏆 Congratulations to @OmniAbTech , Inc. — winner of the Best of Show Award at #PEGSummit 2025!

Their xPloration® Partner Access Program captured attendee votes by a landslide for its innovation and impact.

Thanks to all who participated, and congrats again to the OmniAb team!

[CochranLab @CochranLab]

@PEGSboston @OmniAbTech Congrats to lab alum Bob Chen and the OmniAb team for their Best in Show award at PEGSummit for the xPloration® B cell protein/Ab engineering screening cell platform!

[CochranLab @CochranLab]

Excited to see our lab's B cell screening technology, spearheaded by Cochran alum and xCella Biosciences co-founder Bob Chen, rolled out as a now commercial instrument from antibody discovery company @OmniAbTech.

[OmniAb @OmniAbTech]

OmniAb Showcases Innovative High-Throughput Single B-cell Screening xPloration® Platform at the 21st Annual PEGS Boston Summit
https://t.co/A79IxcdzIJ

[Stanford Bioengineering @bioe_stanford]

Congratulations to Professor Jennifer Cochran @CochranLab who was recently elected to the National Academy of Engineering @theNAEng for protein discovery and development, biotechnology entrepreneurship, and leadership in academic bioengineering!
https://t.co/98pikpPNuf

[Jack Silberstein @Jack_Silb]

I'm excited to share our work "Structural insights reveal interplay between LAG-3 homodimerization, ligand binding, and function" that's now out in PNAS! 1/3

Link to paper: https://t.co/tTqz8a9aIw

Link to press release: https://t.co/BotEe86ztR

[The Journal of Immunology @J_Immunol]

#JI_TopRead from @CaitlynBioE @CochranLab @CarolynBertozzi @StanfordHealth | #TLR9 agonist, PIP-CpG, enhances the CD8 #Tcell response to spontaneous tumors | #ReadTheJI #immunology #AuthorChoice #FreetoRead #TumorImmunology
👉 https://t.co/KdOxutKuLh

[ACIR @ACIR_org]

In the physiologically relevant MMTV-PyMT GEMM model, @CaitlynBioE @BarfiIdit @CarolynBertozzi demonstrated that systemic delivery of a tumor integrin-targeted TLR9 agonist (PIP-CpG) led to sustained elimination [...] https://t.co/buYdr1B1aP

[Caitlyn Miller @CaitlynBioE]

Thrilled to announce that our new PIP-CpG paper is now live @J_Immunol . PIP-CpG is a tumor-targeting immunotherapy that is in preclinical development & we are hoping to advance it to the clinic in the coming years. https://t.co/xsdtrZUP1m .
A 🧵👇(1/13)

[CochranLab @CochranLab]

Congrats to joint @StanfordBioE PhD student @hollander_mj, @CarolynBertozzi and team for this exciting collaborative work!

[Longwood Healthcare Leaders @LongwoodLeaders]

Wonderful insights and leadership from @Stanford @StanfordMed @CochranLab @KarlDeisseroth @drcwestphal
#Longwoodhealthcareleaders

[Sarafan ChEM-H @Stanford_ChEMH]

Congratulations to faculty fellows @alaurenoconnell, @CyertMartha & Jennifer Cochran @CochranLab for winning the 2022 @StanfordMedOFDD Faculty Women’s Forum Awards!

Learn more: https://t.co/Cfz9ZIZjbT

[Ravi.Radhakrishnan @raviradhak]

Immensely enjoyed the reviewing experience and spending the day-and-a-half on @Stanford campus with this special group of people @kumarlabucb @Widya__Mulya @chubaoyolu @TejalADesai and Darelene Soloman of @Agilent. Thank you @StanfordBioE @CochranLab for the hospitality!

[PEGS Summit @PEGSboston]

Join #PEGS22 Plenary Keynote Jennifer Cochran, PhD, today at 4:10pm to discuss challenges and opportunities in developing non-antibody protein therapeutics. https://t.co/ntpm9XOJHJ

[Alina Chrzastek @Evoletto]

TLR9 (CpG) agonist was chemically conjugated to polyspecific integrin-binding peptide (PIP) that is capable to localise various types of solid tumours as explained by Caitlyn Miller from @CochranLab at @Stanford #PEGS22 @PEGSboston

[CochranLab @CochranLab]

Excited to share this collaborative work published in Cell on an exquisite drug-regulated CAR platform. Led by Louai Labanieh, jointly advised Bioengineering PhD student in the lab of @cm35c

[Louai Labanieh @LouaiLabanieh]

Thrilled to announce that our SNIP paper is live @CellCellPress! SNIP is a high-performance drug-regulated CAR platform that is optimized for the clinic--plans for a trial are already underway @StanfordMed.
#CART #Immunotherapy #SynBio #Cancer.
https://t.co/ReaGRoM3iJ
1/

[Cell Press @CellPressNews]

Read Jennifer Cochran's recent @CellChemBiol article: Systemic delivery of a targeted synthetic immunostimulant transforms the immune landscape for effective tumor regression @CochranLab #AACR22 https://t.co/RKd8flXpR9

[CochranLab @CochranLab]

Thrilled to share our exciting collaborative work with @CarolynBertozzi, Ron Levy, @SCIDirector Steve Artandi featured on the cover of @CellChemBiol, led by the talented @CaitlynBioE and @BarfiIdit.

[Caitlyn Miller @CaitlynBioE]

Excited to see our research featured on the cover of this month’s issue of @CellChemBiol. Check out our article “Systemic delivery of a targeted synthetic immunostimulant transforms the immune landscape for effective tumor regression” at https://t.co/fo5ezPYzKe @CarolynBertozzi

[CochranLab @CochranLab]

@Majzner_Lab @JTheruvath_MD Wonderful to collaborate with you on this beautiful and impactful work!